THE TYSABRI® (NATALIZUMAB)
TOUCH® PRESCRIBING PROGRAM
A commitment to patient safety
Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program
The TOUCH Prescribing Program has been designed to facilitate appropriate
use of TYSABRI
TOUCH On-Line is a web-based tool designed to:
Provide real-time access to TYSABRI patient data
Maintain compliance with the TOUCH Prescribing Program
Reduce administrative burden/paperwork for prescribers and infusion sites
Streamline communication to/from prescribers and infusion sites
TOUCH On-Line is accessed with a secure username and password
Enrollment requirements for the TOUCH Prescribing Program
Under the TOUCH Prescribing Program, only prescribers, pharmacies, and infusion sites enrolled in the program are able to prescribe, distribute, or infuse TYSABRI. Only patients who are enrolled in and meet all the conditions of the program may receive TYSABRI
To enroll in the TOUCH Prescribing Program, prescribers and patients are required to understand the risks of treatment with TYSABRI, including PML and other opportunistic infections, and to review, complete, and sign the Patient Enrollment Form, the Start Form, and the Prescriber Enrollment Form (only required for new TYSABRI prescribers)
PML=progressive multifocal leukoencephalopathy.
How to get started with the TOUCH Prescribing Program
If you are already enrolled in the TOUCH®
Prescribing Program:
Review the TOUCH Prescribing Program prescriber educational materials, including the full prescribing information
Educate patients on the benefits and risks of treatment with TYSABRI and ensure that patients receive the Medication Guide, and encourage them to ask questions
Determine every six months whether patient should continue on treatment and submit the TYSABRI Patient Status Report and Reauthorization Questionnaire
Report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen at 1-800-456-2255 as soon as possible